How Does the FDA Coordinate with International Regulators on AI?

Rasit Dinc

Rasit Dinc Digital Health & AI Research

Published: July 10, 2017 | FDA Regulation and Compliance

DOI: 10.5281/zenodo.17999015

Abstract

The rapid integration of Artificial Intelligence (AI) into healthcare is transforming the landscape of medical devices and diagnostics. As AI-powered medical...

How Does the FDA Coordinate with International Regulators on AI?

Author: Rasit Dinc

Introduction

The rapid integration of Artificial Intelligence (AI) into healthcare is transforming the landscape of medical devices and diagnostics. As AI-powered medical technologies become increasingly sophisticated, ensuring their safety, efficacy, and security is a global priority. The U.S. Food and Drug Administration (FDA) is at the forefront of this regulatory challenge, actively collaborating with international partners to establish a harmonized approach to AI in medicine. This article explores how the FDA coordinates with international regulators to navigate the complexities of AI, fostering innovation while safeguarding public health.

The FDA's Collaborative Approach to AI Regulation

The FDA recognizes that a globalized healthcare ecosystem requires a collaborative regulatory strategy. The agency's efforts to coordinate with international regulators on AI are multifaceted, focusing on harmonization, transparency, and the development of shared principles. By working with its global counterparts, the FDA aims to create a predictable and consistent regulatory environment for AI-enabled medical products, which in turn can accelerate patient access to innovative and safe technologies.

The International Medical Device Regulators Forum (IMDRF)

A key platform for the FDA's international collaboration is the International Medical Device Regulators Forum (IMDRF). This voluntary group of medical

device regulators from around the world works to accelerate international medical device regulatory harmonization and convergence. The FDA, along with other member authorities, leverages the IMDRF to address the unique challenges posed by AI in medical devices. The IMDRF provides a venue for regulators to share information, exchange best practices, and develop consensus on regulatory requirements for AI-enabled medical devices [1].

Through the IMDRF, the FDA is actively involved in developing a globally harmonized policy for the entire lifecycle of AI medical devices. This includes pre-market review, post-market surveillance, and change control plans for adaptive AI algorithms. The goal is to establish a common understanding of the evidence required to demonstrate the safety and effectiveness of these complex technologies, reducing regulatory duplication and streamlining market access for manufacturers worldwide [1].

Good Machine Learning Practice (GMLP)

In collaboration with Health Canada and the UK's Medicines and Healthcare products Regulatory Agency (MHRA), the FDA has developed a set of ten guiding principles for Good Machine Learning Practice (GMLP). These principles are intended to promote the development of safe, effective, and high-quality AI/ML-enabled medical devices. The GMLP principles cover the entire lifecycle of an AI/ML model, from data acquisition and model development to performance monitoring and risk management [2].

The GMLP guiding principles emphasize the importance of a multi-disciplinary approach, robust software engineering practices, and a focus on clinical relevance. They also highlight the need for transparency in how AI models are trained and validated, as well as the importance of monitoring their performance in the real world. These principles are not only being adopted within the U.S. but are also being promoted internationally to foster a shared understanding of best practices for AI in healthcare [2].

Harmonization of Regulatory Elements

The FDA's international coordination efforts extend to the harmonization of key regulatory elements for AI-enabled medical devices. The agency is actively engaged in discussions with global partners on topics such as algorithm transparency, risk management, data security, and clinical evaluation. The aim is to align on these critical aspects of AI regulation to ensure a consistent and rigorous approach across different jurisdictions [3].

By harmonizing these regulatory elements, the FDA and its international partners can create a more predictable and efficient regulatory process for manufacturers. This, in turn, can encourage innovation and facilitate the global deployment of safe and effective AI-powered medical technologies. The FDA's commitment to international collaboration is a testament to its understanding that the challenges of AI in healthcare are global in nature and require a coordinated global response [3].

Conclusion

The FDA's coordination with international regulators on AI is a critical

component of its strategy to ensure the safety and effectiveness of AI-enabled medical technologies. Through its leadership in the IMDRF, its collaboration on the GMLP guiding principles, and its efforts to harmonize key regulatory elements, the FDA is helping to build a global consensus on AI regulation. This collaborative approach is essential for fostering innovation, protecting patients, and realizing the full potential of AI to transform healthcare for the better.

References

[1] Scott, M. (2024, May 29). *FDA Eyes Global AI Partnerships to Safeguard Patient Data*. GovCIO Media & Research. Retrieved from https://govciomedia.com/fda-eyes-global-ai-partnerships-to-safeguard-patient-data/

[2] Lu, C.-F., & Abbott, C. K. (2024, April 3). *US FDA to Develop Regulatory Scheme for AI in Medical Products, Foster International Cooperation*. Greenberg Traurig. Retrieved from https://www.gtlaw.com/en/insights/2024/4/us-fda-to-develop-regulatory-scheme-for-ai-in-medical-products-foster-international-cooperation

[3] Reddy, S. (2024). Global Harmonization of Artificial Intelligence-Enabled Software as a Medical Device Regulation: Addressing Challenges and Unifying Standards. *MCP Digital Health*, *3*(1), 100191. https://doi.org/10.1016/j.mcpdig.2024.100191